Logo

Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for the Treatment of COVID-19 Outside the US

Share this

Sanofi and Regeneron Expand Clinical Program of Kevzara (sarilumab) for the Treatment of COVID-19 Outside the US

Shots:

  • The first patient has been treated as a part of the global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The P-II/III clinical program has initiated in Italy- Spain- Germany- France- Canada and Russia and is enrolling patients instantly
  • The study outside the US will assess the safety and efficacy of Kevzara (IV) + SOC vs PBO + SOC and is anticipated to enroll ~300 patients with Regeneron leading US studies and Sanofi leading ex-US studies
  • Kevzara is a mAb inhibiting IL-6 pathway by targeting the IL-6 receptor- currently approved in multiple countries for patients with RA- who have not responded to or tolerated previous therapy

Click here to­ read full press release/ article | Ref: Sanofi | Image: DigitalMax


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions